Aadi Bioscience Inc

About Aadi Bioscience Inc

Aadi Bioscience (NASDAQ:AADI) is a dynamic player in the biotechnology arena, focused on developing and commercializing precision therapies for genetically defined cancers. Their flagship product, FYARRO, is already approved for the treatment of advanced malignant PEComa, an ultra-rare cancer. Utilizing innovative nanotechnology, they aim to harness mTOR inhibitors' potential for broader oncology indications. The company is delving into various clinical trials to expand their drug's applicability across different tumor types characterized by TSC1 and TSC2 mutations and other alterations in the mTOR pathway. Aadi Bioscience is committed to transforming patients' lives through cutting-edge precision medicine, forging new paths in cancer treatment and giving hope to those battling these challenging conditions.

What is Aadi Bioscience Inc known for?

Snapshot

Year founded

Employees

Pacific Palisades, United States

Head office

Loading Map...

Operations

All Locations

United States

Products and/or services of Aadi Bioscience Inc

FYARRO: An mTOR inhibitor approved for treating advanced malignant PEComa, targeting mTOR pathway-driven tumors for patients with limiting treatment options.
Advanced solid tumors studies: Investigations evaluating FYARRO's potential to benefit patients across multiple tumor types with mTOR-driven malignancies.
MLN0128 Development: A potent inhibitor, aiming to expand therapeutic applications and address mTOR pathway anomalies in diverse cancers.
PIK3CA Mutations Research: Projects focusing on addressing genetic mutations to refine precision therapies involving mTOR inhibitors.
Orphan Drug Designations: Initiatives to secure special status for rare disease treatments, ensuring fiscal support and regulatory advantages.
Clinical Collaborations: Partnerships with research bodies to optimize drug development and expand scientific understanding of mTOR pathways.